OBJECTIVE: Although the antiviral agent, @entity1033 , is currently employed for the treatment in @entity6324 , the benefit of @entity1033 on facial nerve is still unknown and remains controversial. This study was designed to evaluate the effect of @entity1033 in facial nerve recovery in @entity6324 . METHODS: To evaluate drug effect on @entity2103 , evaluation of the @entity717 and nerve excitability testing were performed. We have used an infusion therapy of @entity1033 in combination with a high dose of @entity134 ( @entity5427 ), which was started within 7 days of onset of @entity2103 in 91 @entity1 with @entity6324 . The results were compared with those of 47 @entity1 whose therapy was @entity134 alone started within 7 days of onset. RESULTS: Out of 91 @entity1 treated with @entity5427 , nerve exitability was good in 68 (75%), while it was poor in 17 and absent in six. Of 47 @entity1 treated with @entity134 alone, nerve exitability was good in 25 (53%), while it was poor in 11 and absent in 11. There was statistically significant difference between @entity5427 and @entity134 therapy in the posttreatment degree of nerve function. Complete recovery to grade I in @entity717 was attained in 82 of 91 @entity1 (90%) in the @entity5427 therapy, while out of 47 @entity1 treated with @entity134 alone complete recovery to grade I was attained in only 30 (64%). A statistically significant difference in the recovery rate of @entity2103 was induced between @entity5427 and @entity134 therapy. CONCLUSION: The @entity5427 therapy was proved to keep good degree of nerve function indicated with nerve excitability testing and improve recovery rate of facial nerve in @entity6324 . Based on this study, we now believe that the @entity5427 therapy is an advisable treatment modality to improve the recovery rate of @entity2103 in @entity6324 .

@entity1033 improves recovery rate of XXXX in @entity6324 .

@entity1033 :: ('MESH:D000212', 'Chemical') :: ['acyclovir'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5427 :: ('MESH:D017204', 'Disease') :: ['AS'] @entity2103 :: ('MESH:D005155', 'Disease') :: ['facial nerve palsy', 'facial nerve function'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity717 :: ('MESH:D009069', 'Disease') :: ['facial voluntary movement'] @entity6324 :: ('MESH:D016697', 'Disease') :: ['Ramsay Hunt syndrome']
@entity2103 :: (MESH:D005155,Disease) :: ['facial nerve palsy']
